Original language | English |
---|---|
Pages (from-to) | 52-63 |
Number of pages | 12 |
Journal | International Journal of Radiation Oncology Biology Physics |
Volume | 105 |
Issue number | 1 |
DOIs | |
State | Published - 1 Sep 2019 |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: International Journal of Radiation Oncology Biology Physics, Vol. 105, No. 1, 01.09.2019, p. 52-63.
Research output: Contribution to journal › Review article › peer-review
TY - JOUR
T1 - Enhancing Career Paths for Tomorrow's Radiation Oncologists
AU - Vapiwala, Neha
AU - Thomas, Charles R.
AU - Grover, Surbhi
AU - Yap, Mei Ling
AU - Mitin, T.
AU - Shulman, Lawrence N.
AU - Gospodarowicz, Mary K.
AU - Longo, John
AU - Petereit, Daniel G.
AU - Ennis, Ronald D.
AU - Hayman, James A.
AU - Rodin, Danielle
AU - Buchsbaum, Jeffrey C.
AU - Vikram, Bhadrasain
AU - Abdel-Wahab, May
AU - Epstein, Alan H.
AU - Okunieff, Paul
AU - Goldwein, Joel
AU - Kupelian, Patrick
AU - Weidhaas, Joanne B.
AU - Tucker, Margaret A.
AU - Boice, John D.
AU - Fuller, Clifton David
AU - Thompson, Reid F.
AU - Trister, Andrew D.
AU - Formenti, Silvia C.
AU - Barcellos-Hoff, Mary Helen
AU - Jones, Joshua
AU - Dharmarajan, Kavita V.
AU - Zietman, Anthony L.
AU - Coleman, C. Norman
N1 - Funding Information: Disclosures: N.V. has received speaker honoraria from Varian Medical Systems. J.G. is a full-time employee of Elekta AB. P.K. is an employee of Varian Medical Systems. J.B.W. reports other from MiraDx, outside the submitted work, and a patent KRAS-variant in cancer with royalties paid to MiraDx. C.D.F. has received industry-funded institutional grant support, speaker honoraria, and travel funding from Elekta AB. P.O. is an inventor and founder of a company that markets biomarker technologies, DiaCarta.com. S.C.F. reports grant/research support from Bristol Myers Squibb, Varian, Janssen, Regeneron, Eisai, Merck, Celldex and honoraria form Bristol Myers Squibb, Varian, Elekta, Janssen, Regeneron, GlaxoSmithKline, Eisai, Dynavax, AstraZeneca, Merck, Viewray, Bayer. T.M. reports personal fees from UpToDate, Inc and Janssen and grants from Novocure, Inc. The remaining authors do not report any relevant conflicts of interest regarding the sections which they co-authored. Funding Information: Drs Vapiwala, Thomas, and Coleman would like to acknowledge Alicia Livinski, National Institutes of Health Library, for her meticulous assistance in the preparation of this manuscript. Disclosures: N.V. has received speaker honoraria from Varian Medical Systems. J.G. is a full-time employee of Elekta AB. P.K. is an employee of Varian Medical Systems. J.B.W. reports other from MiraDx, outside the submitted work, and a patent KRAS-variant in cancer with royalties paid to MiraDx. C.D.F. has received industry-funded institutional grant support, speaker honoraria, and travel funding from Elekta AB. P.O. is an inventor and founder of a company that markets biomarker technologies, DiaCarta.com. S.C.F. reports grant/research support from Bristol Myers Squibb, Varian, Janssen, Regeneron, Eisai, Merck, Celldex and honoraria form Bristol Myers Squibb, Varian, Elekta, Janssen, Regeneron, GlaxoSmithKline, Eisai, Dynavax, AstraZeneca, Merck, Viewray, Bayer. T.M. reports personal fees from UpToDate, Inc and Janssen and grants from Novocure, Inc. The remaining authors do not report any relevant conflicts of interest regarding the sections which they co-authored.
PY - 2019/9/1
Y1 - 2019/9/1
UR - http://www.scopus.com/inward/record.url?scp=85070195866&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2019.05.025
DO - 10.1016/j.ijrobp.2019.05.025
M3 - Review article
C2 - 31128144
AN - SCOPUS:85070195866
SN - 0360-3016
VL - 105
SP - 52
EP - 63
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 1
ER -